Wolters Kluwer Health
may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
your express consent. For more information, please refer to our Privacy Policy.

ABSTRACT This article presents the case of a cognitively normal patient who is requesting a procedure (amyloid imaging) recently approved for the diagnosis of Alzheimer disease (AD) in patients with cognitive impairment. The predictive value of this test in unaffected people is not clearly established. Knowing the results of the test will have no effect on therapeutic options, although the patient may make lifestyle decisions based on the results. There is potential risk to the patient in terms of insurability, employability, and psychological consequences. Physicians will face this situation with increasing frequency as the AD biomarker field progresses.

Relationship Disclosure: Dr Snider receives research support from Eli Lilly and Company for a clinical drug trial and anticipates serving as a site principal investigator and coinvestigator on such trials in the future. Dr Buckles reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Drs Snider and Buckles report no disclosures.